On November 19, Exelixis fell 4.07% in Regular Trading, trading at $65.64/share, with turnover of $38.00 million.
The move appears tied to weaker analyst sentiment after Morgan Stanley cut its price target to $57 from $60, while RBC had earlier raised its target to $58 from $51 but kept a Sector Perform rating.
That pressure came despite solid quarterly results reported in late October: adjusted EPS was $0.94, above estimates ranging from $0.80 to $0.89, and revenue rose to $658.7 million from $597.8 million, also ahead of consensus. For full-year revenue, Exelixis guided to $2.50 billion to $2.55 billion, with the high end only in line with market expectations, which may have limited upside enthusiasm.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments